Heyuan Biologics

OBiO Technology (also known as Heyuan Biologics) is a leading Chinese Contract Development and Manufacturing Organization (CDMO) specializing in gene and cell therapy (GCT). Founded in 2013 and headquartered in Shanghai, the company provides end-to-end solutions ranging from CRO services for early-stage research to large-scale GMP manufacturing of viral vectors, plasmids, and cell products. OBiO operates state-of-the-art facilities, including the massive OBiO Intelli-M factory in the Lin-gang Special Area, which features 29 production lines for viral vectors and cell therapies. The company is listed on the Shanghai Stock Exchange (STAR Market) and supports a global client base in advancing innovative treatments for oncology, rare diseases, and neurological disorders.